Imunon, Inc. Deferred Income Tax Expense (Benefit)
Imunon, Inc. (IMNN) reported Deferred Income Tax Expense (Benefit) of $1.28 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-31
- Imunon, Inc. deferred income tax expense (benefit) for the quarter ending 2024-12-31 was $0.00.
- Imunon, Inc. deferred income tax expense (benefit) for the quarter ending 2024-09-30 was $0.00.
- Imunon, Inc. deferred income tax expense (benefit) for the quarter ending 2024-06-30 was $0.00.
- Imunon, Inc. deferred income tax expense (benefit) for the quarter ending 2024-03-31 was $1.28M, a 18.29% decline year-over-year.
- Imunon, Inc. deferred income tax expense (benefit) for fiscal 2024 was $1.28M, a 346.69% increase from fiscal 2023.
- Imunon, Inc. deferred income tax expense (benefit) for fiscal 2023 was $286.64K.
- Imunon, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$183.58K, a 139.70% decline from fiscal 2021.
- Imunon, Inc. deferred income tax expense (benefit) for fiscal 2021 was $462.38K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $1.28M 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $1.28M 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.28M 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2025-08-05 | $0.00 derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.28M 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | $0.00 derived: sum of 3 quarters · filed 2025-05-12 | $0.00 derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.28M derived: sum of 2 quarters · filed 2025-02-27 | -$1.28M derived: sum of 3 quarters · filed 2025-02-27 | $286.64K 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $1.57M 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.57M 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-08-14 | $0.00 derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.57M 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | $0.00 derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$1.57M derived: sum of 2 quarters · filed 2024-03-28 | -$1.57M derived: sum of 3 quarters · filed 2024-03-28 | -$183.58K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $1.38M 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.38M 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | $0.00 derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.38M 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | $0.00 derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$1.38M derived: sum of 2 quarters · filed 2023-03-30 | -$1.38M derived: sum of 3 quarters · filed 2023-03-30 | $462.38K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $1.85M 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.85M 10-Q · filed 2022-08-15 | $0.00 derived: sum of 3 quarters · filed 2022-08-15 | $0.00 derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $1.85M 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | $0.00 derived: sum of 3 quarters · filed 2022-05-16 | $0.00 derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.85M derived: sum of 2 quarters · filed 2022-03-31 | -$1.85M derived: sum of 3 quarters · filed 2022-03-31 | -$26.50K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $1.82M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.82M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.82M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$1.82M 10-K · filed 2021-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |